Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.36 |
| ▸ | MGLL | Q99685 | 6/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26631210 | 1.00 | LOXL2 (0.38) | LOXL2ABHD6MGLLSCN9ACCR5 | |
| SCHEMBL26631141 | 0.91 | LOXL2 (0.35) | LOXL2ABHD6MGLLSCN9ACCR5 | |
| SCHEMBL26739501 | 0.91 | LOXL2 (0.35) | LOXL2ABHD6MGLLSCN9ACCR5 | |
| SCHEMBL26631170 | 0.90 | LOXL2 (0.41) | LOXL2MGLLSCN9ARORC | |
| SCHEMBL26739570 | 0.90 | LOXL2 (0.41) | LOXL2MGLLSCN9ARORC | |
| SCHEMBL26748909 | 0.87 | GPR119 (0.41) | GPR119TTR | |
| SCHEMBL25409272 | 0.86 | LOXL2 (0.41) | LOXL2ABHD6MGLLGPR119TTR | |
| SCHEMBL26739491 | 0.84 | MGLL (0.35) | ABHD6MGLLSCN9ACCR5 | |
| SCHEMBL26739495 | 0.84 | MGLL (0.35) | ABHD6MGLLSCN9ACCR5 | |
| SCHEMBL26631358 | 0.82 | GPR119 (0.46) | LOXL2ABHD6MGLLGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | LOXL2 244/4885ABHD6 25/4885MGLL 1/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | LOXL2 253/4885ABHD6 25/4885MGLL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.